Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months
- 16 August 2010
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 28 (36), 5837-5844
- https://doi.org/10.1016/j.vaccine.2010.06.065
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trialVaccine, 2010
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineThe New England Journal of Medicine, 2009
- Response to a Monovalent 2009 Influenza A (H1N1) VaccineThe New England Journal of Medicine, 2009
- Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza VirusThe New England Journal of Medicine, 2009
- Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 monthsVaccine, 2009
- Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress SyndromeJAMA, 2009
- Critically Ill Patients With 2009 Influenza A(H1N1) Infection in CanadaJAMA, 2009
- Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in HumansThe New England Journal of Medicine, 2009
- Strategies for mitigating an influenza pandemicNature, 2006
- Mitigation strategies for pandemic influenza in the United StatesProceedings of the National Academy of Sciences of the United States of America, 2006